# Phosphonite Mediated 1,3-Dipolar Cycloaddition: A Route to Polycyclic 2-Pyrrolines from Imines, Acid Chlorides and Alkenes

Marie S. T. Morin, Sara Aly and Bruce A. Arndtsen\*

801 Sherbrooke St. W., Department of Chemistry, McGill University Montreal, Quebec H3A 2K6 Canada

### **Supporting Information**

I. General Procedures

II. Imine Synthesis

2-4

III. Synthesis of Pyrrolines 3

5-8

IV. Synthesis of Pyrrolidines 4

9-10

V. Synthesis of pyrrole 5k

10

VI. References

10-11

VII. <sup>1</sup>H and <sup>13</sup>C NMR Spectra

#### I. General Procedures

All reactions were performed under an inert nitrogen atmosphere in either a Vacuum Atmospheres 553-2 dry box or using Schlenk techniques. Reagents were purchased from commercial sources and used as received. Solid PPh<sub>3</sub> and PCy<sub>3</sub> were dried by heating at 120°C under high vaccum. Liquid P(OCH<sub>2</sub>CF<sub>3</sub>)<sub>3</sub>, P(OPh)<sub>3</sub> and P(NMe<sub>2</sub>)<sub>3</sub> were dried over 4 A molecular sieves. (2-catechyl)PPh was prepared by a literature procedure. Aldehyde precursors to imines 2a,b,f-m, 2c,e<sup>3</sup> and 2d<sup>4</sup> were prepared by literature procedures. CDCl<sub>3</sub> and CD<sub>3</sub>CN were distilled from CaH<sub>2</sub> under nitrogen. Dichloromethane and diethyl ether were dried via filtration through activated molecular sieves (MBraun SPS). H and Hand To NMR spectra were recorded on Varian Mercury 300 MHz, 400 MHz and Unity 500 MHz spectrometers. The stereochemistry of the pyrroline and pyrrolidine products was determined by NoE NMR experiments (3a, 3f, 4a and 4c), and comparison to literature reported compounds.

## **II. Imine Synthesis**

#### Typical Procedure

To a solution of 2-(allyloxy)benzaldehyde (405.4 mg, 2.5 mmol) in dichloromethane (10 mL) was added MgSO<sub>4</sub> and ethylamine (2.0 M in THF) (1.4 mL, 2.75 mmol). The heterogeneous mixture was stirred at room temperature for 18h. The reaction mixture was filtered, and the solvent and excess amine were evaporated *in vacuo* to provide imine **2a** as a clear oil (402 mg, 85%). In the case of imines **2b**, **2i**, **2j**, **2l** and **2m**, exactly 1.0 equivalent of amine was added.

#### (E)-N-(2-(allyloxy)benzylidene)ethanamine 2a

Fet **H NMR** (400 MHz, CDCl<sub>3</sub>): δ 8.77 (s, 1H), 7.96 (dd, J = 7.7 Hz, 1.7 Hz, 1H), 7.34-7.29 (m, 1H), 6.97 (t, J = 7.5 Hz, 1H), 6.86 (dd, J = 8.4 Hz, 2.1 Hz, 1H), 6.11-6.01 (m, 1H), 5.41 (dt, J = 17.3 Hz, 1.6 Hz, 1H), 5.29 (dt, J = 10.6 Hz, 1.5 Hz, 1H), 4.58-4.55 (m, 2H), 3.65 (qd, J = 7.3 Hz, 1.3 Hz, 2H), 1.30 (t, J = 7.3 Hz, 3H). <sup>13</sup>**C NMR** (126 MHz; CDCl<sub>3</sub>): δ 157.6, 156.3, 133.0, 131.5, 127.3, 125.1, 121.0, 117.5, 112.3, 69.0, 56.2, 16.5. **HRMS** (ESI<sup>+</sup>) for C<sub>12</sub>H<sub>16</sub>NO<sup>+</sup>; calculated: 190.12264, found: 190.12231.

#### (E)-N-(2-(allyloxy)benzylidene)-1-phenylmethanamine 2b

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.91 (s, 1H), 8.06 (dd, J = 7.7 Hz, 1.8 Hz, 1H), 7.37-7.35 (m, 5H), 7.30-7.25 (m, 1H), 7.00 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H), 6.15-6.05 (m, 1H), 5.44 (dd, J = 17.3 Hz, 1.5 Hz, 1H), 5.34-5.31 (m, 1H), 4.86 (s, 2H), 4.62 (d, J = 5.1 Hz, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 157.9<sub>4</sub>, 157.8<sub>6</sub>, 139.7, 133.0, 131.9, 128.4, 128.0, 127.5, 126.8, 124.9, 121.0, 117.6, 112.3, 69.1, 65.5 HRMS (ESI<sup>+</sup>) for C<sub>17</sub>H<sub>18</sub>NO<sup>+</sup>; calculated: 252.13829, found: 252.13766.

#### (E)-N-(2-(but-3-en-1-yl)benzylidene)prop-2-en-1-amine 2c

<sup>1</sup>H NMR (400 MHz; CDCl<sub>3</sub>): δ 8.61 (s, 1H), 7.94 (d, J = 7.7 Hz, 1H), 7.34 (td, J = 7.4 Hz, 1.5 Hz, 1H), 7.26 (t, J = 7.6 Hz, 1H), 7.19 (d, J = 7.6 Hz 1H), 6.10 (ddt, J = 17.1 Hz, 10.4 Hz, 5.6 Hz, 1H), 5.87 (ddt, J = 17.0 Hz, 10.3 Hz, 6.7 Hz, 1H), 5.28-5.15 (m, 2H), 5.08-4.99 (m, 2H), 4.29 (dq, J = 5.6 Hz, 1.5 Hz, 2H), 2.95 (t, J = 7.9 Hz, 2H), 2.35 (q, J = 6.8 Hz, 2H). <sup>13</sup>C NMR (126 MHz; CDCl<sub>3</sub>): δ 160.2, 141.5, 137.6, 136.0, 133.7, 130.3, 130.0, 127.7, 126.4, 115.9, 115.2, 64.0, 36.0, 32.1. HRMS (APCI<sup>+</sup>) for C<sub>14</sub>H<sub>18</sub>N<sup>+</sup>; calculated: 200.14287, found: 200.143338.

#### N-(2-(allylthio)benzylidene)ethanamine 2d

NEt
NEt
NMR (400 MHz; CDCl<sub>3</sub>):  $\delta$  8.85 (s, 1H), 7.92 (dd, J = 7.7 Hz, 1.7 Hz, 1H), 7.40 (dd, J = 7.7 Hz, 1.4 Hz, 1H), 7.31 (td, J = 7,5 Hz, 1.7 Hz, 1H), 7.27-7.23 (m, 1H), 5.82 (ddt, J = 17.0 Hz, 10.0 Hz, 7.0 Hz, 1H), 5.07-5.01 (m, 2H), 3.67 (qd, J = 7.3 Hz, 1.4 Hz, 2H), 3.47 (dt, J = 7.0 Hz, 1.1 Hz, 2H), 1.31 (t, J = 7.3

Hz, 3H). <sup>13</sup>C **NMR** (126 MHz; CDCl<sub>3</sub>):  $\delta$  159.0, 136.6, 136.1, 133.1, 131.8, 130.3, 127.8, 127.1, 118.0, 56.0, 38.3, 16.4. **HRMS** (ESI<sup>+</sup>) for C<sub>12</sub>H<sub>16</sub>NS<sup>+</sup>; calculated: 206.09980, found: 206.09928.

#### *N*-(2-allylbenzylidene)ethanamine **2e**

NEt 
NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ ppm): 8.53 (s, 1H), 7.87 (d, J = 7.5 Hz, 1H), 7.29 (t, J = 7.5 Hz, 1H), 7.23 (t, J = 7.5 Hz, 1H), 7.14 (d, J = 7.5 Hz, 1H), 6.00-5.92 (m, 1H), 5.03 (d, J = 9.0 Hz, 1H), 4.92 (d, J = 17.0 Hz, 1H), 3.63-3.57 (m, 4H), 1.27 (t, J = 7.5 Hz, 3H). 
NMR (75.5 MHz, CDCl<sub>3</sub>)  $\delta$ ppm): 158.8, 139.0, 137.2, 134.4, 130.3, 130.2, 127.5, 126.8, 116.1, 56.4, 36.9, 16.5. HRMS (APCI<sup>+</sup>) for C<sub>12</sub>H<sub>16</sub>N<sup>+</sup>; calculated: 174.12773, found: 174.12772.

### (E)-N-((1-allyl-1H-pyrrol-2-yl)methylene)ethanamine 2f

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.12 (s, 1H), 6.75 (t, J = 2.2 Hz, 1H), 6.50 (dd, J = 3.7 Hz, 1.8 Hz, 1H), 6.17 (dd, J = 3.7 Hz, 2.7 Hz, 1H), 6.03-5.94 (m, 1H), 5.14-5.11 (m, 1H), 5.04-4.96 (m, 3H), 3.51 (qd, J = 7.3 Hz, 1.2 Hz, 2H), 1.23 (t, J = 7.3 Hz, 3H). <sup>13</sup>**C NMR** (126 MHz; CDCl<sub>3</sub>):  $\delta$  151.5, 135.1, 129.4, 126.2, 116.4, 115.8, 108.3, 56.3, 50.6, 16.7. **HRMS** (APCI<sup>+</sup>) for C<sub>10</sub>H<sub>15</sub>N<sub>2</sub><sup>+</sup>; calculated: 163.12298, found: 163.12271.

### N-(2-((E)-but-2-en-1-yloxy)benzylidene)ethanamine 2h

NEt

NEt

NEt

NR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.75-8.74 (m, 1H), 7.93 (dd, J = 7.7 Hz, 1.8 Hz, 1H), 7.34 (ddd, J = 8.3 Hz, 7.3 Hz, 1.8 Hz, 1H), 6.98-6.97 (m, 1H), 6.91-6.88 (m, 1H), 5.90-5.83 (m, 1H), 5.79-5.71 (m, 1H), 4.64-4.48 (m, 2H), 3.67-3.62 (m, 2H), 1.78-1.74 (m, 3H), 1.29 (td, J = 7.3 Hz, 1.1 Hz, 3H). 

NMR (75 MHz, CDCl<sub>3</sub>), with rotamers:  $\delta$  157.8, 156.5, 131.5, 130.3, 128.6, 127.2, 125.9, 125.5, 125.0, 120.9, 120.8, 112.4, 112.2, 69.1, 64.2, 56.1, 17.9, 16.4, 13.4. HRMS (ESI<sup>+</sup>) for  $C_{13}H_{18}NO^+$ ; calculated: 204.13829, found: 204.13784.

#### (E)-ethyl 4-(2-((E)-(hexylimino)methyl)phenoxy)but-2-enoate 2i

NHex  $^{1}$ H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ ppm): 8.73 (s, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.33 (t, J = 8.4 Hz, 1H), 7.10 (dt, J = 4.0, 16.0 Hz, 1H), 7.01 (t, J = 7.6 Hz, 1H), 6.85 (d, J = 8.4 Hz, 1H), 6.18 (d, J = 16.0 Hz, 1H), 4.75 (d, J = 4.0 Hz, 2H), 4.22 (q, J = 7.2 Hz, 2H), 3.63 (t, J = 6.8 Hz, 2H), 1.72–1.66 (m, 2H), 1.39–1.29 (m, 9H), 0.89 (t, J = 7.2 Hz, 3H);  $^{13}$ C NMR (125.7 MHz, CDCl<sub>3</sub>)  $\delta$ ppm): 166.0, 157.0, 156.2, 142.1, 131.5, 127.6, 125.3, 122.2, 121.5, 112.0, 66.8, 62.1, 60.6, 31.7, 31.0, 27.0, 22.6, 14.2, 14.1; HRMS (ESI $^{+}$ ) for  $C_{19}H_{28}NO_{3}^{+}$ ; calculated: 318.20637, found: 318.20591.

### (E)-ethyl 4-(2-((E)-(benzylimino)methyl)phenoxy)but-2-enoate 2j

NBn

1H NMR (400 MHz; CDCl<sub>3</sub>):  $\delta$  8.88 (s, 1H), 8.05 (dd, J = 7.7 Hz, 1.7 Hz, 1.17 Hz, 1H), 7.37-7.35 (m, 5H), 7.27-7.24 (m, 1H), 7.11 (dt, J = 15.8 Hz, 4.1 Hz, 1H), 7.02 (t, J = 7,5 Hz, 1H), 6.87 (d, J = 8.3 Hz, 1H), 6.18 (dt, J = 15.8 Hz, 2.0 Hz, 1H), 4.86 (d, J = 1.2 Hz, 2H), 4.77 (dd, J = 4.1 Hz, 2.0 Hz, 2H), 4.24 (q, J = 7.1 Hz, 2H), 1.32 (t, J = 7.1 Hz, 3H). 13°C NMR (126 MHz, CDCl<sub>3</sub>):  $\delta$  165.9, 157.4, 157.2, 142.0, 139.5, 131.9, 128.5, 128.0<sub>1</sub>, 127.8<sub>2</sub>, 126.9, 125.0, 122.2, 121.5, 112.1, 66.9, 65.4, 60.6, 14.3. HRMS (ESI<sup>+</sup>) for C<sub>20</sub>H<sub>22</sub>NO<sub>3</sub><sup>+</sup>; calculated: 324.15942, found: 324.15888.

### (E)-N-(2-(cinnamyloxy)benzylidene)ethanamine 2k

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.82 (s, 1H), 8.00 (dd, J = 7.7 Hz, 1.7 Hz, 1H), 7.45-7.43 (m, 2H), 7.39-7.34 (m, 3H), 7.29 (t, J = 7.3 Hz, 1H), 7.03-6.95 (m, 2H), 6.75 (d, J = 16.0 Hz, 1H), 6.45 (dt, J = 16.0 Hz, 5.8 Hz, 1H), 4.76 (dd, J = 5.8 Hz, 1.1 Hz, 2H), 3.68 (qd, J = 7.3 Hz, 1.3 Hz, 2H), 1.33 (t, J = 7.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ 157.7, 156.4, 136.3, 133.1, 131.6, 128.7, 128.0, 127.4, 126.6, 125.1, 124.2, 121.1, 112.4, 69.1, 56.2, 16.5. HRMS (ESI<sup>+</sup>) for C<sub>18</sub>H<sub>20</sub>NO<sup>+</sup>; calculated: 266.15394, found: 266.15345.

#### (E)-ethyl 4-((1-((E)-(benzylimino)methyl)naphthalen-2-yl)oxy)but-2-enoate 21


<sup>1</sup>H NMR (400 MHz; CDCl<sub>3</sub>): δ 9.25 (d, J = 8.7 Hz, 1H), 9.20 (t, J = 1.4 Hz, 1H), 7.87 (d, J = 9.1 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.53 (ddd, J = 8.6 Hz, 6.9 Hz, 1.5 Hz, 1H), 7.47 (d, J = 8.2 Hz, 2H), 7.41-7.35 (m, 2H), 7.31-7.26 (m, 2H), 7.19-7.11 (m, 2H), 6.23 (dt, J = 15.7 Hz, 2.0 Hz, 1H), 4.99 (s, 2H), 4.88 (dd, J = 4.0 Hz, 2.0 Hz, 2H), 4.24 (q, J = 7.1 Hz, 2H), 1.32 (t, J = 7.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz; CDCl<sub>3</sub>): δ 166.0, 159.4, 156.5, 142.1, 139.7, 132.6, 132.1, 129.5, 128.5, 128.2, 128.1, 126.9, 125.9, 124.4, 122.3, 118.2, 113.6, 68.0, 66.8, 60.7, 14.3. HRMS (ESI<sup>+</sup>) for C<sub>24</sub>H<sub>24</sub>NO<sub>3</sub><sup>+</sup>; calculated: 374.17507, found: 374.17396.

#### (E)-N-(2-(allyloxy)benzylidene)hexan-1-amine 2m

<sup>1</sup>**H NMR** (400 MHz; CDCl<sub>3</sub>): δ 8.74 (s, 1H), 7.96 (dd, J = 7.7 Hz, 1.7 Hz, 1H), 7.35-7.31 (m, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H), 6.12-6.03 (m, 1H), 5.43 (dd, J = 17.3 Hz, 1.6 Hz, 1H), 5.30 (dt, J = 10.6 Hz, 1.3 Hz, 1H), 4.59 (td, J = 3.4 Hz, 1.7 Hz, 2H), 3.62 (td, J = 7.1 Hz, 1.1 Hz, 2H), 1.70 (quintet, J = 7.3 Hz, 2H), 1.39-1.30 (m, 6H), 0.89 (t, J = 7.0 Hz, 3H). <sup>13</sup>C NMR (126 MHz; CDCl<sub>3</sub>): δ 157.6, 156.6, 133.1, 131.5, 127.3, 125.2, 121.0, 117.5, 112.3, 69.1, 62.1, 31.7, 31.0, 27.1, 22.6, 14.1. **HRMS** (ESI<sup>+</sup>) for C<sub>16</sub>H<sub>24</sub>NO<sup>+</sup>; calculated: 246.18524, found: 246.18461.

### III. Synthesis of Pyrrolines 3

#### Synthesis and characterization of 3a.




In the glovebox, imine 2a (37.8 mg, 0.2 mmol) and toluoyl chloride (32.5 mg, 0.21 mmol) were mixed in CDCl<sub>3</sub> (ca. 0.5 mL) and allowed to stand 30 min. (2-catechyl)PPh (47.5 mg, 0.22 mmol) was added and after 1h at room temperature, DBU (45.7 mg, 0.3 mmol) was added, and the volume of CDCl<sub>3</sub> adjusted to 1.5 mL. The reaction was complete within 10 min at

room temperature. The solution was concentrated in vacuo, and the residue dissolved in minimum amount of CH<sub>2</sub>Cl<sub>2</sub>. The product is purified in a glovebox with small pipette column of alumina using diethyl ether as eluent, affording 3a as a light yellow oil (49.5 mg, 85%).

<sup>1</sup>**H NMR**: (500 MHz, CDCl<sub>3</sub>) δppm): 7.31 (d, J = 7.5 Hz, 1H), 7.26-7.21 (m, 3H), 7.15 (d, J =7.5 Hz, 2H), 6.98-6.93 (m, 2H), 4.79 (d, J = 2.0 Hz, 1H), 4.35 (d, J = 8.0 Hz, 1H), 4.06 (dd, J =10.5 Hz, 4.5 Hz, 1 H), 3.83 (t, J = 10.5 Hz, 1H), 3.32-3.21 (m, 2H), 3.09-3.04 (m, 1H), 2.36 (s, 3H), 0.98 (t, J = 7.0 Hz, 3H). <sup>13</sup>C NMR: (125.7 MHz, CDCl<sub>3</sub>)  $\delta$ ppm): 155.5, 155.0, 137.8, 131.3, 130.9, 128.9, 128.7, 127.2, 122.0, 120.4, 117.2, 101.0, 66.3, 57.4, 40.4, 38.6, 21.2, 10.1. **HRMS** (ESI<sup>+</sup>) for C<sub>20</sub>H<sub>22</sub>NO<sup>+</sup>; calculated: 292.16959, found: 292.16908.

#### Synthesis and characterization of **3b**



**3b** was prepared according to the same procedure as **3a**. Isolated yield: 85%.

<sup>1</sup>**H NMR**: (500 MHz, CD<sub>3</sub>CN)  $\delta$ ppm): 7.49 (dd, J = 8.15 Hz, 1.42 Hz, 2H), 7.40-7.31 (m, 7H), 7.27 (td, J = 6.16 Hz, 3.04 Hz, 1H), 7.17-7.12 (m, 2H), 6.85-6.81 (m, 2H), 5.08 (d, J = 2.25 Hz, 1H), 4.41 (d, J = 8.30 Hz, 1H), 4.32(d, J = 15.91 Hz, 1H), 4.27 (d, J = 15.90 Hz, 1H), 4.05 (dd, J = 11.03 Hz, 4.23 Hz, 1H), 3.95 (dd, J = 15.91 Hz, 1Hz)J = 11.02 Hz, 7.63 Hz, 1H), 3.20 (dtd, J = 10.21 Hz, 5.03 Hz, 2.86 Hz, 1H). <sup>13</sup>C NMR: (125.7) MHz, CD<sub>3</sub>CN) δppm): 161.0, 159.8, 144.2, 138.9, 136.3, 133.8, 133.7, 133.6, 132.4, 132.2. 128.5, 125.9, 122.0, 109.3, 71.6, 63.9, 57.3, 45.3. **HRMS** (ESI<sup>+</sup>) for  $C_{24}H_{22}NO^+$ ; calculated:

#### Synthesis and characterization of 3d

340.16959, found: 340.16954.

3d was prepared according to the same procedure as 3a, except the cycloaddition required 2 h to go to completion. Isolated yield: 95%.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δppm): 7.47–7.45 (m, 1H), 7.40–7.35 (m, 3H), 7.22-7.15 (m, 4H), 4.83 (s, 1H), 4.43 (d, J = 10.4 Hz, 1H), 3.83-3.78(m, 1H), 3.15 (sx, J = 7.2 Hz, 1H), 2.97-2.88 (m, 2H), 2.58 (dd, J = 6.8 Hz, 12.8 Hz, 11), 2.37(s, 3H), 0.92 (t, J = 7.2 Hz, 3H), <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>)  $\delta$ ppm): 154.1, 137.9, 137.5, 136.9, 131.0, 130.1, 129.4, 129.0, 127.1, 127.0, 125.4, 104.8, 63.1, 45.8, 42.2, 34.0, 21.3, 10.8. **HRMS** (APCI<sup>+</sup>) for  $C_{20}H_{22}NS^+$ ; calculated: 308.14675, found: 308.14622.


#### Synthesis and characterization of 3e

H Et N p-Tol

**3e** was prepared according to the same procedure as **3a**. Isolated yield: 74%.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.51–7.47 (m, 1H), 7.35–7.31 (m, 2H), 7.29–7.18 (m, 3H), 7.09 (d, J = 7.9 Hz, 2H), 5.05 (d, J = 2.1 Hz, 1H), 4.79 (d, J = 8.3 Hz, 1H), 4.04 (t, J = 8.3 Hz, 1H), 3.26 (dd, J = 16.2 Hz, 8.3 Hz, 1H), 3.19–3.05 (m, 1H), 2.98 (ddd, J = 17.4 Hz, 11.0 Hz, 4.3 Hz, 2H), 2.31 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 151.2, 145.4, 142.0, 137.5, 131.2, 128.8, 127.6, 127.0, 126.5, 125.5, 124.9, 109.6, 72.7, 46.3, 45.9, 38.3, 21.3, 14.3. HRMS (ESI<sup>+</sup>) for C<sub>20</sub>H<sub>22</sub>N<sup>+</sup>: calculated: 276.17468, found: 276.17430.


#### Synthesis and characterization of 3f



**3f** was prepared according to the same procedure as **3a** with the exception that CD<sub>3</sub>CN was used as solvent. Isolated yield: 76%. **1H NMR** (400 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  7.29 (d, J = 6.4 Hz, 2H), 6.87 (d, J = 7.6 Hz,

**H NMR** (400 MHz, C<sub>6</sub>D<sub>6</sub>) δ 7.29 (d, J = 6.4 Hz, 2H), 6.87 (d, J = 7.6 Hz, 2H), 6.57–6.47 (m, 1H), 6.38 (dd, J = 2.6 Hz, 1.3 Hz, 1H), 6.22 (dd, J = 3.5 Hz, 1.2 Hz, 1H), 4.66 (d, J = 2.3 Hz, 1H), 4.52 (d, J = 9.5 Hz, 1H), 3.87–3.71 (m, 1H), 3.51 (dd, J = 10.1 Hz, 8.2 Hz, 1H), 3.42 (dd, J = 10.1 Hz, 4.1 Hz, 1H), 3.11 (dq, J = 14.5 Hz, 7.2 Hz, 1H), 2.71 (dq, J = 13.9 Hz, 7.0 Hz, 1H), 2.02 (s, 3H), 1.05 (t, J = 7.1 Hz, 3H). <sup>13</sup>C **NMR** (75 MHz, C<sub>6</sub>D<sub>6</sub>) δ 153.1, 138.4, 137.5, 131.4, 128.8, 113.6, 113.5, 103.0, 100.7, 65.6, 52.3, 50.1, 45.2, 20.8, 13.8. **HRMS** (APCI<sup>+</sup>) for C<sub>18</sub>H<sub>21</sub>N<sub>2</sub><sup>+</sup>; calculated: 265.16993, found: 265.16930.

### Synthesis and characterization of 3g



In the glovebox, imine **2a** (37.8 mg, 0.2 mmol) and trimethylacetyl chloride (26.5 mg, 0.22 mmol) were mixed in CDCl<sub>3</sub> (ca. 0.5 mL) and allowed to stand 30 min. (2-catechyl)PPh (47.5 mg, 0.22 mmol) was added and after 18h at room temperature, DBU (45.7 mg, 0.3 mmol) was added, and the volume of

CDCl<sub>3</sub> adjusted to 1.5 mL. The reaction was complete after 10 min at rt. The solution was concentrated in vacuo, and the residue dissolved in minimum amount of CH<sub>2</sub>Cl<sub>2</sub>. The product is purified in a glovebox with small pipette column of alumina using diethyl ether as eluent, affording **3g** as a light yellow oil (33 mg, 68%).

<sup>1</sup>**H NMR** (400 MHz; CDCl<sub>3</sub>): δ 7.28 (dd, J = 7.6 Hz, 1.4 Hz, 1H), 7.19 (t, J = 8.4 Hz, 1H), 6.94-6.87 (m, 2H), 4.54 (d, J = 2.2 Hz, 1H), 4.21 (d, J = 7.7 Hz, 1H), 3.97 (dd, J = 10.7 Hz, 4.6 Hz, 1H), 3.66 (t, J = 10.0 Hz, 1H), 3.51-3.26 (m, 2H), 2.91-2.85 (m, 1H), 1.21 (t, J = 6.8 Hz, 3H), 1.16 (s, 9H). <sup>13</sup>**C NMR** (101 MHz; CDCl<sub>3</sub>): δ 161.4, 155.6, 130.9, 128.5, 121.8, 120.2, 117.0, 97.7, 66.3, 57.5, 40.7, 37.3, 30.0, 26.5, 11.4. **HRMS** (ESI<sup>+</sup>) for C<sub>17</sub>H<sub>24</sub>NO; calculated: 258.18524 found: 258.18491.


#### Synthesis and characterization of 3h

**3h** was prepared according to the same procedure as **3a**, with the exception that cycloaddition required 1h at 60°C. Isolated yield: 88%.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.18 (m, 4H), 7.04 (m, 2H), 7.00–6.88 (m, 2H), 4.25 (d, J = 8.0 Hz, 1H), 4.20 (dd, J = 10.8 Hz, 4.4 Hz, 1H), 3.93 (t, J = 10.3 Hz, 1H), 3.20–2.95 (m, 3H), 1.71 (s, 3H), 0.95 (t, J = 7.0

Hz, 3H). <sup>13</sup>C **NMR** (75 MHz, CDCl<sub>3</sub>)  $\delta$  161.9 (d, <sup>1</sup> $J_{C-F}$  = 237.5 Hz), 155.5, 145.4, 130.9, 130.4 (d, <sup>3</sup> $J_{C-F}$  = 7.5 Hz), 128.7 (d, <sup>4</sup> $J_{C-F}$  = 3.0 Hz), 128.6, 122.4, 120.5, 117.1, 115.1 (d, <sup>2</sup> $J_{C-F}$  = 15.0 Hz), 110.0, 64.8, 56.1, 42.9, 40.8, 11.8, 10.0. **HRMS** (APCI<sup>+</sup>) for C<sub>20</sub>H<sub>21</sub>NOF<sup>+</sup>; calculated: 310.16017, found: 310.16097.

#### Synthesis and characterization of 3i




In the glovebox, imine **2i** (63.5 mg, 0.2 mmol) and 2-thiophenecarbonyl chloride (32.2 mg, 0.22 mmol) were mixed in CDCl<sub>3</sub> (ca. 0.5 mL) and allowed to stand 30 min. (2-catechyl)PPh (47.5 mg, 0.22 mmol) was added and after 1h at room temperature, DBU (60.8 mg, 0.4 mmol) was added, and

the volume of CDCl<sub>3</sub> adjusted to 1.5 mL. The reaction was complete within 10 min at room temperature. The product was purified by column chromatography on silica using hexanes/diethyl ether 95/5 as the eluent, affording **3i** as a light yellow oil (65.8 mg, 80%).

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ (ppm): 7.45 (d, J = 3.9 Hz, 1H), 7.29-7.22 (m, 2H), 7.08-7.03 (m, 2H), 6.98-6.94 (m, 2H), 4.68 (d, J = 8.4 Hz, 1H), 4.33 (dd, J = 4.8 Hz, 10.4 Hz, 1H), 4.05-3.96 (m, 2H), 3.82 (t, J = 10.8 Hz, 1H), 3.41-3.35 (m, 1H), 3.07 (t, J = 8.4 Hz, 2H), 1.72-1.65 (m, 1H), 1.31-1.06 (m, 10H), 0.83 (t, J = 6.8 Hz, 3H); <sup>13</sup>**C NMR** (75.5 MHz, CDCl<sub>3</sub>) δppm): 165.2, 156.2, 155.6, 131.1, 131.0, 129.6, 128.7, 127.2, 126.7, 120.5, 118.4, 117.8, 101.4, 65.0, 58.8, 58.5, 44.2, 37.9, 31.2, 27.4, 26.3, 22.4, 14.2, 13.9; **HRMS** (ESI<sup>+</sup>) for C<sub>24</sub>H<sub>30</sub>NO<sub>3</sub>S<sup>+</sup>; calculated: 412.19409 found: 412.19430.

### Synthesis and characterization of 3i



Pyrroline **3j** was prepared according to the same procedure as **3i**. Isolated yield: 89%.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ ppm): 7.37 (t, J = 7.6 Hz, 3H), 7.29-7.21 (m, 3H), 7.17 (d, J = 7.6 Hz, 2H), 6.98 (d, J = 7.6 Hz, 1H), 6.94-6.88 (m, 3H), 6.83 (t, J = 7.2 Hz, 1H), 4.79 (d, J = 8.8 Hz, 1H), 4.48 (d, J = 16.8 Hz, 1H), 4.37 (dd, J = 4.8 Hz, 11.2 Hz, 1H), 4.20 (d, J = 16.8 Hz, 1H), 4.11-4.01 (m, 2H), 3.96 (t, J = 10.8 Hz, 1H), 3.79 (s, 3H), 3.56-3.50 (m, 1H), 1.12 (t, J = 6.8 Hz, 3H); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>)  $\delta$ ppm): 165.7, 163.4, 160.1, 156.5, 137.1, 131.3, 130.1, 129.5, 128.8, 127.2, 127.0, 123.6, 120.4, 118.5, 117.7, 113.5, 98.6, 65.9, 58.8, 57.6, 55.2, 47.5, 38.5, 14.4. HRMS (ESI<sup>+</sup>) for C<sub>28</sub>H<sub>28</sub>NO<sub>4</sub><sup>+</sup>; calculated: 442.20128, found: 442.20053.

### Synthesis and characterization of 3k

Pyrroline 3k was prepared according to the same procedure as 3h. Isolated yield: 91%.

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.32–7.15 (m, 6H), 7.09 (t, J = 7.7 Hz, 2H), 7.00-6.94 (m, 5H), 4.50 (d, J = 7.9 Hz, 1H), 4.18 (dd, J = 10.9 Hz, 4.8 Hz, 1H), 3.91 (t, J = 11.0 Hz, 1H), 3.33-3.56 (m, 1H), 3.24-3.04 (m, 2H), 2.41 (s, 3H), 1.01 (t, J =7.0 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 155.7, 148.7, 138.0, 135.7, 131.1<sub>3</sub>, 131.0<sub>8</sub>, 129.6, 129.1, 129.0, 128.1, 126.0, 124.2, 120.7, 120.3, 117.3, 110.6, 65.0, 56.1, 39.9, 38.9, 21.4, 10.5. **HRMS** (APCI<sup>+</sup>) for C<sub>26</sub>H<sub>26</sub>NO<sup>+</sup>; calculated: 368.20089, found: 368.19963.

#### Synthesis and characterization of 31




476.22177.

Pyrroline 31 was prepared according to the same procedure as 3i. Isolated

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.79–7.60 (m, 3H), 7.37–7.17 (m, 4H), 7.17– 7.07 (m, 6H), 6.69–6.59 (m, 2H), 5.69 (d, J = 9.4 Hz, 1H), 4.20–4.10 (m,  $CO_2Et$  3H), 4.07–3.91 (m, 3H), 3.66 (dt, J = 9.3 Hz, 5.9 Hz, 1H), 2.33 (s, 3H), 1.06 (t, J = 7.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  165.9, 163.6, 156.1, 138.9, 138.4, 133.7, 130.1, 129.2, 128.8, 128.7, 128.0, 126.7, 126.5, 123.5, 122.0, 119.3, 112.3, 98.9, 67.3, 58.6, 55.6, 48.1, 40.3, 21.4, 14.3, 14.1. **HRMS** (APCI<sup>+</sup>) for  $C_{32}H_{30}NO_3^+$ ; calculated: 476.22202, found:

# IV. Synthesis of Pyrrolidines 4

#### Synthesis and characterization of 4c




In the glovebox, imine 2c (39.8 mg, 0.2 mmol) and benzoyl chloride (29.5 mg, 0.21 mmol) were mixed in CDCl<sub>3</sub> (ca. 0.5 mL) and allowed to stand 30 min. (2-catechyl)PPh (47.5 mg, 0.22 mmol) was added and after 1h at room temperature, DBU (45.7 mg, 0.3 mmol) was added, and the volume of CDCl<sub>3</sub> adjusted to 1.5 mL. The reaction was complete within 10 min at

room temperature. To the crude reaction mixture in a 25 mL round bottom flask was added NaBH(OAc)<sub>3</sub> (64 mg, 0.3 mmol) followed by HCl, 1M in Et<sub>2</sub>O (400 μl, 0.4 mmol). The solution is stirred at rt for 18h and then guenched with 4 mL of 2N NaOH. The product is extracted with dichloromethane, washed with water, then dried with MgSO<sub>4</sub>, filtered and concentrated. The product is purified by flash column chromatography on silica using petroleum ether/diethyl ether as eluent (90/10), affording 4c as a white foam (43.4 mg, 75%).

<sup>1</sup>**H NMR** (400 MHz; CDCl<sub>3</sub>): δ 7.39-7.36 (m, 2H), 7.32-7.28 (m, 3H), 7.26-7.22 (m, 4H), 6.03-5.92 (m, 1H), 5.13 (d, J = 10.2 Hz, 1H), 5.01 (d, J = 17.1 Hz, 1H), 3.90 (d, J = 8.8 Hz, 1H), 3.81 (dd, J = 9.9 Hz, 6.6 Hz, 1H), 3.20 (dd, J = 13.6 Hz, 6.4 Hz, 1H), 3.10-2.98 (m, 2H), 2.63-2.56 (m, 2Hz), 2.2H), 2.43 (ddd, J = 12.4 Hz, 8.5 Hz, 6.4 Hz, 1H), 1.74-1.70 (m, 2H), 1.61 (ddd, J = 12.3 Hz, 10.1 Hz, 8.4 Hz, 1H). <sup>13</sup>C NMR (126 MHz; CDCl<sub>3</sub>): δ 143.5, 141.1, 137.8, 132.9, 129.7, 128.3, 128.0, 127.6, 127.0, 126.7, 125.4, 118.2, 65.4, 62.2, 51.0, 41.9, 34.8, 30.4, 27.0. **HRMS** (APCI<sup>+</sup>) for  $C_{21}H_{24}N^{+}$ ; calculated: 290.19033, found: 290.18968.

#### 1-ethyl-2-(p-tolyl)-1,2,3,3a,4,9b-hexahydrochromeno[4,3-b]pyrrole, 4a



4a was prepared according to the same procedure as 4c. Isolated yield:

<sup>1</sup>**H NMR** (500 MHz, CDCl<sub>3</sub>)  $\delta$ ppm): 7.26-7.20 (m, 4H), 7.12 (d, J = 8 Hz, 2H), 6.93 (d, J = 7.5 Hz, 2H), 4.18 (t, J = 10.5 Hz, 1H), 4.05 (dd, J = 10.5Hz, 4.5 Hz, 1H), 3.83 (t, J = 8.5 Hz, 1H), 3.70 (d, J = 5.5 Hz, 1H), 2.87 (dt, J = 14.5 Hz, 7 Hz, 1H), 2.74 (dt, J = 14.5 Hz, 7 Hz, 1H), 2.51-2.45 (m, 1H), 2.42-2.35 (m, 1H), 2.33 (s, 3H) 1.31-1.26 (m, 1H), 0.95 (t, J = 7 Hz, 3H). <sup>13</sup>C NMR (125.7 MHz, CDCl<sub>3</sub>)  $\delta$ ppm): 155.2, 141.1, 136.5, 131.4, 129.1, 128.6, 127.3, 122.2, 119.9, 116.9, 67.4, 64.1, 57.4, 41.2, 36.1, 33.3, 21.1, 8.2. **HRMS** (ESI<sup>+</sup>) for C<sub>20</sub>H<sub>24</sub>NO<sup>+</sup>; calculated: 294.18524, found: 294.18454.

#### Synthesis and characterization of 4m



In the glovebox, imine 2m (49.1 mg, 0.2 mmol) and ethyl chlorothioformate (27.4 mg, 0.22 mmol) were mixed in CDCl<sub>3</sub> (ca. 0.5 mL) and allowed to stand 30 min at 50°C. (2-catechyl)PPh (47.5 mg, 0.22 mmol) was added and after 1h at 50°C, DBU (60.8 mg, 0.4 mmol) was added, and the volume of CDCl<sub>3</sub> adjusted

to 1.5 mL. The reaction was complete within 10 min at room temperature. To the crude reaction mixture in a 25 mL round bottom flask was added NaBH(OAc)<sub>3</sub> (85 mg, 0.4 mmol) followed by

HCl, 1M in Et<sub>2</sub>O (400  $\mu$ l, 0.4 mmol). The solution is stirred at rt for 18h and then quenched with 4 mL of 2N NaOH. The product is extracted with dichloromethane, washed with water, then dried on MgSO<sub>4</sub>, filtered and concentrated. The product is purified by flash column chromatography on silica using petroleum ether/diethyl ether as eluent 90/10, affording **4m** as a white foam (19.2 mg, 37%).

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δ 7.21–7.16 (m, 2H), 6.91–6.87 (m, 2H), 4.05–3.91 (m, 2H), 3.17-3.13 (m, 1H), 3.08-2.98 (m, 2H), 2.41-2.34 (m, 1H), 2.23-2.19 (m, 2H), 2.08-2.01 (m, 1H), 1.54–1.35 (m, 3H), 1.27-1.24 (m, 6H), 0.86 (t, J = 6.6 Hz, 3H). <sup>13</sup>**C NMR** (75 MHz, CDCl<sub>3</sub>) δ 155.2, 131.9, 128.6, 121.7, 119.6, 116.8, 67.6, 61.5, 53.3, 50.9, 34.3, 31.8, 28.4, 27.3, 24.6, 22.6, 14.1. **HRMS** (APCI<sup>+</sup>) for C<sub>17</sub>H<sub>26</sub>NO<sup>+</sup>; calculated: 260.20131, found: 260.20199.

### V. Synthesis of Pyrrole 5k

Et N-P-Tol

The crude reaction mixture of pyrroline **3k** described above was dissolved in THF (5 mL). To this solution was added 1,4-benzoquinone (75 mg, 0.7 mmol). The solution is refluxed at 90 °C for 1 h, followed by the addition of more 1,4-benzoquinone (21.6 mg, 0.2 mmol). This solution was heated at

90 °C for 3 h. The product was purified by flash column chromatography on silica using hexanes/diethyl ether as eluent 90/10, affording **5k** as a white foam (48 mg, 65%).

<sup>1</sup>**H NMR** (400 MHz, CDCl<sub>3</sub>) δppm): 7.48 (d, J = 7.6 Hz, 1H), 7.26-7.20 (m, 6H), 7.15-7.10 (m, 2H), 7.05-6.99 (m, 4H), 5.30 (s, 2H), 4.18 (q, J = 7.1 Hz, 2H), 2.40 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H). <sup>13</sup>**C NMR** (126 MHz; CDCl<sub>3</sub>): δ 153.6, 137.7, 134.8, 133.4, 131.3, 129.2, 129.1<sub>7</sub>, 129.1, 128.1, 126.5, 125.4, 122.8, 121.7, 120.6, 119.8, 119.2, 117.4, 115.3, 65.1, 40.1, 21.4, 16.6. **HRMS** (APCI<sup>+</sup>) for C<sub>26</sub>H<sub>24</sub>NO<sup>+</sup>; calculated: 366.18524, found: 366.18440.


#### VI. References


- 1. D. J. St-Cyr, M. S. T. Morin, F. Bélanger-Gariépy, B. A. Arndtsen, E. H. Krenske and K. N. Houk, *J. Org. Chem.*, 2010, **75**, 4261.
- 2. J. Pospisil and M. Potacek, *Tetrahedron*, 2007, **63**, 337.
- 3. S. Arai, Y. Koike, H. Hada and A. Nishida, *J. Org. Chem.*, **75**, 7573.
- 4. S. Saubern, J. M. Macdonald, J. H. Ryan, R. C. J. Woodgate, T. S. Louie, M. J. Fuchter, J. M. White and A. B. Holmes, *Tetrahedron*, 2010, **66**, 2761.
- 5. R. W. Layer, *Chem. Rev.*, 1963, **63**, 489.


6. (a) A. Khlebnikov, M. Novikov, R. Kostikov and J. Kopf, *Russ. J. Org. Chem.*, 2005, **41**, 1341; (b) S. Kanemasa, K. Sakamoto and O. Tsuge, *Bull. Chem. Soc. Jpn.*, 1989, **62**, 1960; (c) J. Pospíšil and M Potáček, *Tetrahedron*, 2007, **63**, 337.


# VII. <sup>1</sup>H and <sup>13</sup>C NMR spectra









































### Imine 2e (CDCl<sub>3</sub>)





### Imine 2f (CDCl<sub>3</sub>)




ppm











### Imine 2i (CDCl<sub>3</sub>)






































### Pyrroline 3a (CDCl<sub>3</sub>)










### Pyrroline **3b** (CD<sub>3</sub>CN)









#### Summary of NOEs of key correlations in C<sub>6</sub>D<sub>6</sub>




# Pyrroline 3d (CDCl<sub>3</sub>)




### Pyrroline 3e (CDCl<sub>3</sub>)








# Pyrroline **3f** (C<sub>6</sub>D<sub>6</sub>)




### NOE of key correlation in CDCl<sub>3</sub>










### Pyrroline 3i (CDCl<sub>3</sub>)







# Pyrroline 3k (CDCl<sub>3</sub>)





### Pyrroline 31 (CDCl<sub>3</sub>)







### Pyrrolidine 4a (CDCl<sub>3</sub>)












#### NOEs of key correlations



### Pyrrolidine 4m (CDCl<sub>3</sub>)

